Itero Biopharmaceuticals raises $21M for proteins and antibodies
Itero Biopharmaceuticals, a San Mateo, Calif. startup working with follow-on and therapeutic proteins and antibodies, raised a $21 million first round of financing and announced a partnership with Biological E., an Indian manufacturing firm.
Alongside its partner, Itero will begin development of differentiated follow-on proteins and work on securing patents and approvals for worldwide distribution, with multiple other product lines planned for the future.
SV Life Sciences, which is listed as the largest shareholder, and Panorama Capital led the round, with participation from VenturEast.
Next Story: RepairPal turns the key on car site, setting stage for DriverSide rivalry
Previous Story: The real iPhone 3G rip-off: Text messages
About the Author, Chris Morrison
Chris Morrison writes about cleantech and environmental issues for VentureBeat, with occasional forays into gaming and semantic technology. He got his start writing about tech for Business 2.0 magazine, but quickly realized new media was the ticket when that institution closed its doors in 2007. Chris has also covered public equities and regulatory issues. He originally hails from southern Virginia, graduated from Evergreen State College in Washington, and now lives in San Francisco.